Eli Lilly’s weight loss drug Zepbound shows promise as a sleep apnea treatment in late-stage trials

CNBC April 17, 2024
Annika Kim Constantino

Key Points

– Eli Lilly said its highly popular weight loss drug Zepbound showed the potential to treat patients with the most common sleep-related breathing disorder in two late-stage clinical trials.

– Zepbound was more effective than a placebo at reducing the severity of obstructive sleep apnea in patients with obesity after a year.

– The pharmaceutical giant said it plans to present the preliminary trial data at an upcoming medical conference and submit them to the Food and Drug Administration and regulators in other countries mid-2024.

Eli Lilly on Wednesday said its highly popular weight loss drug Zepbound showed the potential to treat patients with the most common sleep-related breathing disorder in two late-stage clinical trials.

The initial...

Today's Sponsors

Today's Sponsor